Mont-saint-guibert, Belgium

Cardio3 BioSciences

www.c3bs.com
Mont-saint-guibert, Belgium
SEARCH FILTERS
Time filter
Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: NMP.2013.2.2-1 | Award Amount: 8.69M | Year: 2013

The Advanced Materials for Cardiac Regeneration (AMCARE) consortium aims to establish a translational research program to develop truly restorative therapies for acute myocardial infarction repair (MI) by optimising cardiac progenitor cell (CPC) therapy using smart biomaterials and advanced drug delivery, and coupling these therapeutics with minimally-invasive surgical devices. Two distinct biomaterial delivery systems for CPCs will be investigated in the AMCARE work programme including HA-based patches (CardioPatch) and HA-hydrogels (CardioGel). We also propose to develop two prototypes of new surgical devices [C-CathGel and SPREDS] that will ensure a minimally invasive delivery and fixation approach that is safe and effective for each therapeutic. The combinations of advanced material carriers and surgical devices will be assessed in a large animal model of acute-MI to best align our approach to clinical translation. The novel formulations and delivery methods will help post-MI patients in restoring cardiac function by targeting for repair the underlying myocardium damage, and could potentially decrease morbidity and mortality in the future. These goals will be achieved by integrating numerous areas of materials science and stem cell biology as well as leaders in the field of medical devices, biomaterials and cardiovascular regeneration. We thus aim to improve long-term healthcare of EU citizens by offering a revolutionary therapeutic modality for the treatment of acute-MI.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: NMP.2013.2.2-1 | Award Amount: 5.74M | Year: 2014

Approximately 42% of infants mortality in the world is related to congenital heart defects (prevalence: 8-12/1000 births). Over 1/3 require the reconstruction of the right ventricular outflow tract (RVOT) by surgical procedures which currently use inert materials without any growth potential. Consequently, multiple reoperations are often required, with their attendant high risk of mortality and morbidity. The TEH-TUBE project will address these limitations by creating a novel bioabsorbable biomaterial using a polymeric valved tube either seeded with autologous adipose tissue derived stem cells (ADSC) or functionalized by a peptidic sequence triggering homing of the host cells onto the scaffold to make it a living self-populated structure. During the project we will: Compare 3 different polymers (polydioxanone, polyhydroxyalkanoate, poly-ester-urethane-ureas) processed by electrospinning to generate a competent valved tube Compare, in the selected polymer, ADSC seeding and peptide grafting using in vitro mechanical and biological tests as well as in vivo animal experiments (primarily rats) Validate the ultimate combination (polymer \ cells or peptides) in a clinically relevant large animal model (in this case, the growing lamb to specifically assess the regenerative and growth potential of the composite construct) This stepwise approach will be conducted within a tightly controlled regulatory framework to ensure that the final product meets the current ATMP requirements for phase I/II clinical studies and, if successful, ultimate commercialization. Our TEH-TUBE project aims at developing an innovative biomaterial for the treatment of congenital heart abnormalities in children and young adults. By creating a material whose growth will keep pace with that of the patient, this product, geared to become an ATMP, should decrease the risk of reoperative surgeries, improve the quality of life and ultimately have a positive impact on healthcare costs.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.4-1;HEALTH.2011.1.4-2 | Award Amount: 7.84M | Year: 2011

Although the long term prognosis of patients suffering acute myocardial infarction (AMI) has improved since the introduction of reperfusion therapies and primary angioplasty, the 1 year mortality of patients with AMI and resultant left ventricular systolic dysfunction (LVSD) is still as high as 13%. A major reason for the high morbidity and mortality is that the heart has an inadequate regenerative response to the myocardial necrosis sustained following AMI; cell death from the ischaemic damage can lead to progressive ventricular dilation and dysfunction through the processes of vascular remodelling. Despite the use of full conventional treatment, including ACE inhibitors, beta-blockers, aldosterone inhibitors and diuretics, yearly mortality rates of patients with post-infarction heart failure are still in the range of 13 % and rehospitalisation for worsening of heart failure occurs at a yearly rate of 68%. Clinical data now exists supporting the concept that autologous bone marrow derived cells can restore cardiac function following AMI. We plan to advance this research in the BAMI project and will: Develop a standardised method of bone marrow cell collection Develop a standardised method of optimising reparative potential of bone marrow derived cells Standardise bone marrow preparation procedure so that it can be universally applied Standardise method of bone marrow cell delivery post AMI Conduct the first large scale all course mortality clinical trial to test if the product and delivery method mentioned above can lead to a 25% reduction in mortality end-point at 2 years Our project will establish the therapeutic value of this approach to stem cell therapy. Success will demonstrate that transcoronary infusion of bone marrow-derived progenitor cells is safe and will reduce the mortality rate by 25% and reduce the rehospitalisation rate by 15%.


Patent
Cardio3 BioSciences and Mayo Foundation For Medical Education And Research | Date: 2010-05-20

This document is related to a method for determining the cardio-generative potential of mammalian cells which comprises the assessment of a CARdiac generation Potential Index (CARPI) as a function of the quantification of the expression of genes of said cells. It also relates to a method for quantitatively assessing the modification of this cardio-generative potential and the cardiogenic potential of a treatment aiming at cellular differentiation.


Patent
Mayo Foundation For Medical Education And Research and Cardio3 BioSciences | Date: 2016-06-21

This document is related to a method for determining the cardio-generative potential of mammalian cells which comprises the assessment of a CARdiac generation Potential Index (CARPI) as a function of the quantification of the expression of genes of said cells. It also relates to a method for quantitatively assessing the modification of this cardio-generative potential and the cardiogenic potential of a treatment aiming at cellular differentiation.


Patent
Cardio3 BioSciences | Date: 2010-04-29

The invention relates to an injection catheter for delivering a therapeutic agent into a substrate, comprising one or more lumens and a curved delivery element, said lumen serving as a guide for said curved delivery element outside of the substrate; said curved delivery element comprising openings on its distal tip, said distal tip comprising a distal zone and a proximal zone, said injection catheter being characterized in that the specific surface in said distal zone of said distal tip of said curved delivery element is higher than the specific surface in said proximal zone of said distal tip of said curved delivery element. The invention also relates to a process for delivering a therapeutic agent into a substrate.


The application teaches a therapeutic agent for use in the treatment of cardiac warm ischemia reperfusion injury, wherein said therapeutic agent is capable of interacting with at least one of the CD80 or CD86 polypeptides, and wherein said interaction interferes with the binding of the at least one of the CD80 or CD86 polypeptides to the CD28 polypeptide. The application also teaches a therapeutic agent for use in the treatment of cardiac warm ischemia reperfusion injury, wherein said therapeutic agent is capable of preventing or inhibiting the expression of at least one of the CD80 or CD86 polypeptides by a cell or on the surface of a cell.


Patent
Cardio3 BioSciences | Date: 2016-04-20

The invention relates to an injection catheter for delivering a therapeutic agent into a substrate, comprising one or more lumens and a curved delivery element, said lumen serving as a guide for said curved delivery element outside of the substrate; said curved delivery element comprising openings on its distal tip, said distal tip comprising a distal zone and a proximal zone, said injection catheter being characterized in that the specific surface in said distal zone of said distal tip of said curved delivery element is higher than the specific surface in said proximal zone of said distal tip of said curved delivery element. The invention also relates to a process for delivering a therapeutic agent into a substrate.


Patent
Cardio3 BioSciences | Date: 2010-05-20

The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the administration of said pharmaceutical composition which comprises a container containing said pharmaceutical composition.


News Article | January 8, 2015
Site: www.european-biotechnology-news.com

08.01.2015 - Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m. With the deal comes Oncyte's portfolio of immuno-oncology product candidates: three autologous Chimeric Antigen Receptor(CAR) T-Cell cell therapy products and an allogeneic T-Cell platform, targeting a broad range of cancer indications. The CAR technology developed by Oncyte uses human natural killer cell receptors which, unlike traditional CAR technologies, have the potential to target a broad range of liquid and solid cancers via a human natural receptor that targets ligands present on most tumour types. Oncyte’s most advanced autologous CAR T-Cell drug candidate, CM-CS1, uses a specific human Natural Killer cell receptor, NKG2D, that targets tumour antigens expressed in most liquid and solid cancers. The drug candidate is set to start phase I trials in the first quarter of 2015, with the final results expected in mid-2016. For Oncyte, Cardio3 will spend up to US$180m (€153m). There will be an upfront payment of US$6m in cash and US$4m in Cardio3 shares. For the successful development of the lead product CM-CS1, Cardio3 will pay up to US$50m in development and regulatory milestones until market approval, as well as US$21m for each of the other products. Celdara is also eligible for up to US$80m in sales milestones when net sales will exceed US$1bn, as well as royalties. "This acquisition positions us in a second therapeutic area characterised by significant unmet medical need, while allowing us to leverage our leading cell therapy capabilities to drive the development of this potentially game-changing immuno-oncology technology," commented Christian Homsy, CEO of Cardio3 BioSciences.

Loading Cardio3 BioSciences collaborators
Loading Cardio3 BioSciences collaborators